More on SLBT
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.56 |
|
|||
| Open | $1.56 | ||||
| 52 Wk High | $53.95 | ||||
| 52 Wk Low | $44.11 | ||||
| Day High | $1.59 | ||||
| Day Low | $1.42 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 284,543 | ||||
- SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company
- SL Science licensor files FDA drug master file for GDT exosomes
- SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform
- SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma
- SL Science Holding (SLBT) files for 1.04M share offering by selling stockholders
- SL Science presents glioblastoma cell therapy data at WCP 2026
- SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology
- Form 6-K SL Science Holding Ltd For: Jul 10
- SL Science files FDA orphan drug request for GDT glioblastoma therapy
- SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma
Entities mentioned with SLBT
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Barclays | View Related Stories »
- H.C. Wainwright | View Related Stories »
- BofA/Merrill Lynch | View Related Stories »
- Show More...
